Chimpanzee-human monoclonal antibodies for treatment of chronic poliovirus excretors and emergency postexposure prophylaxis

Journal of Virology

Volumn 85, Issue 9, 2011, Pages 4354-4362

  Chen, Zhaochun ^a   Chumakov, Konstantin ^b   Dragunsky, Eugenia ^b   Kouiavskaia, Diana ^b   Makiya, Michelle ^a   Neverov, Alexander ^b   Rezapkin, Gennady ^b   Sebrell, Andrew ^a   Purcell, Robert ^a  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^b CENTER FOR BIOLOGICS EVALUATION AND RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY A12; MONOCLONAL ANTIBODY A6; MONOCLONAL ANTIBODY B10; MONOCLONAL ANTIBODY B2; MONOCLONAL ANTIBODY C10; MONOCLONAL ANTIBODY H2; ORAL POLIOMYELITIS VACCINE; POLIOMYELITIS VACCINE; PROTEIN VP1; PROTEIN VP2; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; BINDING SITE; CHIMPANZEE; CONTROLLED STUDY; EMERGENCY TREATMENT; FEMALE; IMMUNIZATION; INFECTION SENSITIVITY; MALE; MOUSE; NONHUMAN; PARALYSIS; POLIOMYELITIS; POLIOMYELITIS VIRUS; POST EXPOSURE PROPHYLAXIS; PRIORITY JOURNAL; SEROTYPE; TRANSGENIC MOUSE; VIRUS MUTANT; VIRUS NEUTRALIZATION; VIRUS STRAIN;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODIES, NEUTRALIZING; ANTIVIRAL AGENTS; CROSS REACTIONS; DISEASE MODELS, ANIMAL; FEMALE; HUMANS; IMMUNOGLOBULIN G; MALE; MICE; MICE, TRANSGENIC; PAN TROGLODYTES; POLIOMYELITIS; POLIOVIRUS; POST-EXPOSURE PROPHYLAXIS; RECOMBINANT PROTEINS; SEROTYPING;

MIRIDAE; MUS MUSCULUS; PAN; POLIOVIRUS;

EID: 79955381647     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.02553-10     Document Type: Article

References (43)

1. Alexander, L. N., et al. 2004. Vaccine policy changes and epidemiology of poliomyelitis in the United States. JAMA 292:1696-1701.
2. Anonymous. 1993. Maintenance and distribution of transgenic mice susceptible to human viruses: memorandum from a WHO meeting. Bull. World Health Organ. 71:497-502.
3. Belnap, D. M., et al. 2000. Three-dimensional structure of poliovirus receptor bound to poliovirus. Proc. Natl. Acad. Sci. U. S. A. 97:73-78.
4. Chen, Z., et al. 2007. Characterization of chimpanzee/human monoclonal antibodies to vaccinia virus A33 glycoprotein and its variola virus homolog in vitro and in a vaccinia virus mouse protection model. J. Virol. 81:8989-8995.
5. Chen, Z., et al. 2006. Chimpanzee/human mAbs to vaccinia virus B5 protein neutralize vaccinia and smallpox viruses and protect mice against vaccinia virus. Proc. Natl. Acad. Sci. U. S. A. 103:1882-1887.
6. Chen, Z., et al. 2009. Potent neutralization of anthrax edema toxin by a humanized monoclonal antibody that competes with calmodulin for edema factor binding. Proc. Natl. Acad. Sci. U. S. A. 106:13487-13492.
7. Chen, Z., et al. 2006. Efficient neutralization of anthrax toxin by chimpanzee monoclonal antibodies against protective antigen. J. Infect. Dis. 193:625- 633.
8. Chumakov, K., and E. Ehrenfeld. 2008. New generation of inactivated poliovirus vaccines for universal immunization after eradication of poliomyelitis. Clin. Infect. Dis. 47:1587-1592.
9. Colston, E., and V. R. Racaniello. 1994. Soluble receptor-resistant poliovirus mutants identify surface and internal capsid residues that control interaction with the cell receptor. EMBO J. 13:5855-5862.
10. Committee on Development of a Polio Antiviral and Its Potential Role in Global Poliomyelitis Eradication, National Research Council. 2006. Exploring the role of antiviral drugs in the eradication of polio. National Academies Press, Washington, DC.
11. Dessain, S. K., et al. 2004. High efficiency creation of human monoclonal antibody-producing hybridomas. J. Immunol. Methods 291:109-122.
12. Dowdle, W. R., E. De Gourville, O. M. Kew, M. A. Pallansch, and D. J. Wood. 2003. Polio eradication: the OPV paradox. Rev. Med. Virol. 13:277-291.
13. Ehrenfeld, E., et al. 2008. Immunisation against poliomyelitis: moving forward. Lancet 371:1385-1387.
14. Ehrenfeld, E., J. Modlin, and K. Chumakov. 2009. Future of polio vaccines. Expert Rev. Vaccines 8:899-905.
15. Fox, J. P., and C. E. Hall. 1980. Viruses in families: surveillance of families as a key to epidemiology of virus infections, p. 131-135. PSG Publishing Company, Inc., Littleton, MA.
16. Hammon, W. M. 1955. Passive immunization against poliomyelitis. Monogr. Ser. World Health Organ. 26:357-370.
17. Heymann, D. L., R. W. Sutter, and R. B. Aylward. 2005. A global call for new polio vaccines. Nature 434:699-700.
18. Humphrey, D., O. M. Kew, and P. M. Feorino. 1982. Neutralizing monoclonal antibodies of four different specificities for type 1 poliovirus. Infect. Immun. 36:841-843.
19. Ivanov, A. P., and E. M. Dragunsky. 2005. ELISA as a possible alternative to the neutralization test for evaluating the immune response to poliovirus vaccines. Expert Rev. Vaccines 4:167-172.
20. Kew, O. M., et al. 1998. Prolonged replication of a type 1 vaccine-derived poliovirus in an immunodeficient patient. J. Clin. Microbiol. 36:2893-2899.
21. Kew, O. M., et al. 2004. Circulating vaccine-derived polioviruses: current state of knowledge. Bull. World Health Organ. 82:16-23.
22. MacLennan, C., et al. 2004. Failure to clear persistent vaccine-derived neurovirulent poliovirus infection in an immunodeficient man. Lancet 363:1509- 1513.
23. Melnick, J. L.1955. Antigenic crossings within poliovirus types. Proc. Soc. Exp. Biol. Med. 89:131-133.
24. Minor, P. 2001. Characteristics of poliovirus strains from long-term excretors with primary immunodeficiencies. Dev. Biol. (Basel) 105:75-80.
25. Minor, P. 2009. Vaccine-derived poliovirus (VDPV): impact on poliomyelitis eradication. Vaccine 27:2649-2652.
26. Minor, P. D. 1986. Antigenic structure of poliovirus. Microbiol. Sci. 3:141- 144.
27. Mohammed, A. J., et al. 2010. Fractional doses of inactivated poliovirus vaccine in Oman. N. Engl. J. Med. 362:2351-2359.
28. National Institutes of Health. 1985. Guide for the care and use of laboratory animals. NIH publication no. 85-23. U.S. Department of Health and Human Services, Washington, DC.
29. Oberste, M. S., et al. 2009. In vitro antiviral activity of V-073 against polio-viruses. Antimicrob. Agents Chemother. 53:4501-4503.
30. Pallansch, M. A., and R. P. Roos. 2001. Enteroviruses: polioviruses, cox-sackieviruses, echoviruses, and newer enteroviruses, p. 723-775. In D. M. Knipe, P. M. Howley, D. E. Griffin, R. A. Lamb, M. A. Martin, B. Roizman, and S. E. Straus (ed.), Fields virology, 4th ed. Lippincott Williams and Wilkins, Philadelphia, PA.
31. Resik, S., et al. 2010. Randomized controlled clinical trial of fractional doses of inactivated poliovirus vaccine administered intradermally by needle-free device in Cuba. J. Infect. Dis. 201:1344-1352.
32. Rezapkin, G. V., E. Dragunsky, and K. Chumakov. 2005. Improved ELISA test for determination of potency of inactivated poliovirus vaccine (IPV). Biologicals 33:17-27.
33. Rezapkin, G. V., et al. 2010. Repertoire of antibodies against type 1 poliovirus in human sera. J. Virol. Methods 169:322-331.
34. Rinaldo, C. R., Jr. 2005. Passive immunization against poliomyelitis: the Ham-mon gamma globulin field trials, 1951-1953. Am. J. Public Health 95:790-799.
35. Sabin, A. B. 1957. Properties and behavior of orally administered attenuated poliovirus vaccine. JAMA 164:1216-1223.
36. Salk, J. E., et al. 1954. Formaldehyde treatment and safety testing of experimental poliomyelitis vaccines. Am. J. Public Health Nations Health 44:563-570.
37. Steinitz, M., G. Klein, S. Koskimies, and O. Makel. 1977. EB virus-induced B lymphocyte cell lines producing specific antibody. Nature 269:420-422.
38. Traggiai, E., et al. 2004. An efficient method to make human monoclonal antibodies from memory B cells: potent neutralization of SARS coronavirus. Nat. Med. 10:871-875.
39. Uhlig, H., and R. Dernick. 1988. Intertypic cross-neutralization of poliovi-ruses by human monoclonal antibodies. Virology 163:214-217.
40. Uhlig, H., G. Rutter, and R. Dernick. 1983. Evidence for several unrelated neutralization epitopes of poliovirus, type 1, strain Mahoney, provided by neutralization tests and quantitative enzyme-linked immunosorbent assay (ELISA). J. Gen. Virol. 64:2809-2812.
41. Uhlig, J., K. Wiegers, and R. Dernick. 1990. A new antigenic site of poliovirus recognized by an intertypic cross-neutralizing monoclonal antibody. Virology 178:606-610.
42. Wien, M. W., S. Curry, D. J. Filman, and J. M. Hogle. 1997. Structural studies of poliovirus mutants that overcome receptor defects. Nat. Struct. Biol. 4:666-674.
43. World Health Organization. 1997. Manual for the virological investigation of polio. World Health Organization, Geneva, Switzerland.